现在纳米技术

我们NanoNews文摘赞助商
国际小母牛

维基百科的加盟巴顿

>vwinchina德赢> IZON科学接收来自博尔顿股票$ 10.5M投资:基督城总部纳米技术公司作保投入,加快全球经济增长;任命顶部董事长和董事

抽象:
IZON科学,纳米生物分离和表征工具全球领先制造商,今天宣布了一项$ 10.5M的股权投资,以支持从博尔顿股票,基于新西兰的私募股权投资由新西兰商人和企业家穆雷博尔顿目前其雄心勃勃的全球增长计划。

IZON科学接收来自博尔顿股票$ 10.5M投资:基督城总部纳米技术公司作保投入,加快全球经济增长;任命顶部董事长和董事

基督城,新西兰|发表于2020年7月28日

IZON在50多个国家,包括所有的前10名医疗研究公司,排名前10位的制药公司9和49的美国排名前50的大学提供蓝筹股研究客户。感兴趣的特定领域是细胞外囊泡,包括外来体,并期望这些都将成为强大的生物标记物和全球显著医疗水平的提高。



Hans van der Voorn, CEO of Izon Science, says: �We are very pleased to welcome Bolton Equities as a shareholder to help Izon execute on its vision to grow into a truly global business. The investment will allow us to accelerate the development of several new technologies that will further help scientists working at the nano-scale to solve important research questions.�

Chris Dineen, CEO of Bolton Equities, says: �Izon captured our interest as it�s developing technology that science really needs. We were impressed with its product suite�s capabilities, recent growth rates, and the management team�s approach to developing the technology in a very pragmatic way. We also saw that we could bring significant value to the business alongside our capital, leveraging Bolton Equities� strengths in finance, tech and healthcare across key markets.�



Izon�s nano-biological technology and tools include its qEV SEC columns which have rapidly become the extra-cellular vesicles (EV) separation method favoured by experts, and its TRPS measurement system which is the only accurate, standardisable and practical method of measuring complex nano-bio particles, particularly EVs and nanomedicine products.

Izon�s board has been bolstered to coincide with the investment. Tony Barclay, former Fisher & Paykel Healthcare (FPH) CFO and Company Secretary, has been appointed independent chairman and Professor Merryn Tawhai, FRSNZ, the Deputy Director of the Auckland Bioengineering Institute (ABI) and Director of the Medical Technologies Centre of Research Excellence (MedTech CORE), has been appointed as an independent director. Chris Dineen has also been appointed to the board with Guy Bolton, Bolton Equities� Director and President North America, an experienced pharmaceutical and health tech executive based in the US.



Van der Voorn says, �We�re delighted to have attracted Tony as our new chairman as his extensive background is highly relevant to Izon. Merryn, Chris and Guy also add significant expertise that will be invaluable as we work to make a global impact.�



Barclay says, �Hans and the Izon team have really impressed me - they are taking on the world and winning from New Zealand in a fast growing global niche for nanotech identification and separation technology. I recognise similar characteristics in the company to Fisher & Paykel Healthcare; the company is developing impressive technology that is helping move science forward globally to improve lives. The opportunity is open-ended as the company has the potential to become integral to global diagnosis and therapeutics markets.�



Barclay adds that there are bigger players in the wider market addressing these areas in different ways, but Izon�s technology is gaining a reputation as the leader in the field. �A nice element to the business is the multiple streams of revenue it has created due to its expanding range of nanotech instruments and consumables.�

Dineen adds, �Izon is well-positioned to continue its growth despite COVID-19. The company has demonstrated its ability to respond to disruption and is seeing ongoing demand for their technology from its research customers.�

Much of the demand for Izon�s technology in recent years has been driven by the burgeoning interest in extra-cellular vesicles, including exosomes, and their role in a range of health conditions and major diseases such as dementia and cancer.



Van der Voorn says, �We�re enabling fundamental new science as Izon�s tools and technology allow researchers to simultaneously measure particle size and concentration, with sub-nm precision. We�re opening up new nano-biological research areas that haven�t been previously possible at the same scale and accuracy.


�We�re really excited to see our technology being used for research into exosomes, extracellular vesicles and RNA, as researchers work to identify biomarkers which hold the key to early disease intervention. Biomarkers are a measurable indicator of a biological state and play an important role in risk prediction, screening and diagnosis. Identifying biomarkers associated with a type of cancer, would allow medical researchers to see if a cancer treatment was effective or not, by giving faster feedback on pharmacologic responses to a therapeutic intervention.�


Izon has also seen increasing interest in the application of its technology in virology as researchers around the world seek to better understand COVID-19 and other viruses by using information on virus characterisation and concentrations derived from using Izon�s nano-tech tools. Heightened interest in virology and diagnostics and therapeutic drug development will benefit the company longer-term says van der Voorn.

未来的计划还可能包括NZX上市增加的van der Voorn。�We had started preparing for a possible listing prior to this investment, and that is still an option, but it would now be a few years down the track.�

####

关于科学IZON
IZON科学是纳米生物分离和表征工具全球领先制造商。它QEV SEC列已迅速成为专家的青睐EV分离方法。Izon�s TRPS measurement system is the only accurate, standardisable and practical method of measuring complex nano-bio particles, particularly EVs and nanomedicine products.

关于博尔顿股票

www.boltonequities.co.nz

欲了解更多信息,请点击这里

联系方式:
桑德拉Lukey,服务集团(公关IZON)
电话:+64 21 2262 858

版权所有©IZON科学

如果您有任何意见,请联系我们。

新闻发布,不是第七波,公司或现在纳米技术的发行人,是内容的准确性负责vwin徳赢官网。

书签:
美味的掘客Newsvine谷歌雅虎书签交易Magnoliacom卷起之物Facebook的

相关新闻新闻

新闻与信息

箭头制药主机上ARO-ENaC的关键意见领袖研讨会囊性纤维化治疗2020年7月28日

研究:映射晶体形状可以快速跟踪二维材料:专家呼吁全球共同努力清晰障碍批量生产2020年7月27日

俄罗斯科学家钠离子电池阳极的识别能量存储机构2020年7月24日

镀银金纳米星发现早期癌症生物标志物:新的光学传感平台可以在患者的组织中直接检测基因组癌症生物标记2020年7月24日

VC /资金/天使投资/贷款/租赁/众筹

180个资本公司报告Q1 2020结果和发展从Q2 20202020年5月6日

180度资本公司生命科学投资公司进入最终协议将予收购2020年5月6日

180度资本公司报告15.9%,年均增长及净资产每股价值为0.3%,较上季度增长至$ 3.06为2019年12月31日,2020年2月24日

180度资本公司于报告第四季度2019周一,2020年2月24日,并举行电话会议上周二,2020年2月25日的财务业绩2020年2月20日

可能的期货

箭头制药主机上ARO-ENaC的关键意见领袖研讨会囊性纤维化治疗2020年7月28日

研究:映射晶体形状可以快速跟踪二维材料:专家呼吁全球共同努力清晰障碍批量生产2020年7月27日

俄罗斯科学家钠离子电池阳极的识别能量存储机构2020年7月24日

镀银金纳米星发现早期癌症生物标志物:新的光学传感平台可以在患者的组织中直接检测基因组癌症生物标记2020年7月24日

投资/ IPO的/拆分

180个资本公司报告Q1 2020结果和发展从Q2 20202020年5月6日

180度资本公司选择通过养老基金管理$ 2500万2020年5月6日

180度资本公司生命科学投资公司进入最终协议将予收购2020年5月6日

箭头制药在即将举行的2020年5会议参加2020年5月1日

奈米

箭头制药主机上ARO-ENaC的关键意见领袖研讨会囊性纤维化治疗2020年7月28日

镀银金纳米星发现早期癌症生物标志物:新的光学传感平台可以在患者的组织中直接检测基因组癌症生物标记2020年7月24日

HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow�s Diagnostics at the Point of Care2020年7月21日

木炭武器来战斗超源性疾病,损伤:纳米材料吸收自由基,可以帮助COVID-19的治疗2020年7月2日

通告

箭头制药主机上ARO-ENaC的关键意见领袖研讨会囊性纤维化治疗2020年7月28日

研究:映射晶体形状可以快速跟踪二维材料:专家呼吁全球共同努力清晰障碍批量生产2020年7月27日

俄罗斯科学家钠离子电池阳极的识别能量存储机构2020年7月24日

镀银金纳米星发现早期癌症生物标志物:新的光学传感平台可以在患者的组织中直接检测基因组癌症生物标记2020年7月24日

工具

研究:映射晶体形状可以快速跟踪二维材料:专家呼吁全球共同努力清晰障碍批量生产2020年7月27日

项目创造更强大,丰富的超快激光脉冲:光学研究组记录了最短的激光脉冲新开发的技术,即在工程和生物医学重要的应用工作研究所2020年7月24日

科学家们打开新窗口,进入纳米世界2020年7月17日

掺杂氮用于电子器件和量子计算多孔石墨烯带2020年7月10日

纳米生物技术

箭头制药主机上ARO-ENaC的关键意见领袖研讨会囊性纤维化治疗2020年7月28日

镀银金纳米星发现早期癌症生物标志物:新的光学传感平台可以在患者的组织中直接检测基因组癌症生物标记2020年7月24日

HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow�s Diagnostics at the Point of Care2020年7月21日

木炭武器来战斗超源性疾病,损伤:纳米材料吸收自由基,可以帮助COVID-19的治疗2020年7月2日

NanoNews消化
来自世界各地的最新消息,FREE




顶级产品
NanoNews  - 自定义
只有你想要阅读的新闻!
学到更多
NanoStrategies
全方位服务,专家咨询
学到更多